Cargando…
Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis
Antimicrobial resistance continues to be a global issue. Pathogens, such as Burkholderia pseudomallei, have evolved mechanisms to efflux certain antibiotics and manipulate the host response. New treatment strategies are therefore required, such as a layered defense approach. Here, we demonstrate, us...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269878/ https://www.ncbi.nlm.nih.gov/pubmed/37199641 http://dx.doi.org/10.1128/spectrum.04016-22 |
_version_ | 1785059271139917824 |
---|---|
author | Thom, R. E. Williamson, E. D. Casulli, J. Butcher, W. A. Burgess, G. Laws, T. R. Huxley, P. Ashfield, R. Travis, M. A. D’Elia, R. V. |
author_facet | Thom, R. E. Williamson, E. D. Casulli, J. Butcher, W. A. Burgess, G. Laws, T. R. Huxley, P. Ashfield, R. Travis, M. A. D’Elia, R. V. |
author_sort | Thom, R. E. |
collection | PubMed |
description | Antimicrobial resistance continues to be a global issue. Pathogens, such as Burkholderia pseudomallei, have evolved mechanisms to efflux certain antibiotics and manipulate the host response. New treatment strategies are therefore required, such as a layered defense approach. Here, we demonstrate, using biosafety level 2 (BSL-2) and BSL-3 in vivo murine models, that combining the antibiotic doxycycline with an immunomodulatory drug that targets the CD200 axis is superior to antibiotic treatment in combination with an isotype control. CD200-Fc treatment alone significantly reduces bacterial burden in lung tissue in both the BSL-2 and BSL-3 models. When CD200-Fc treatment is combined with doxycycline to treat the acute BSL-3 model of melioidosis, there is a 50% increase in survival compared with relevant controls. This benefit is not due to increasing the area under the concentration-time curve (AUC) of the antibiotic, suggesting the immunomodulatory nature of CD200-Fc treatment is playing an important role by potentially controlling the overactive immune response seen with many lethal bacterial infections. IMPORTANCE Traditional treatments for infectious disease have focused on the use of antimicrobial compounds (e.g. antibiotics) that target the infecting organism. However, timely diagnosis and administration of antibiotics remain crucial to ensure efficacy of these treatments especially for the highly virulent biothreat organisms. The need for early antibiotic treatment, combined with the increasing emergence of antibiotic resistant bacteria, means that new therapeutic strategies are required for organisms that cause rapid, acute infections. Here, we show that a layered defense approach, where an immunomodulatory compound is combined with an antibiotic, is better than an antibiotic combined with a relevant isotype control following infection with the biothreat agent Burkholderia pseudomallei. This approach has the potential to be truly broad spectrum and since the strategy includes manipulation of the host response it's application could be used in the treatment of a wide range of diseases. |
format | Online Article Text |
id | pubmed-10269878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-102698782023-06-16 Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis Thom, R. E. Williamson, E. D. Casulli, J. Butcher, W. A. Burgess, G. Laws, T. R. Huxley, P. Ashfield, R. Travis, M. A. D’Elia, R. V. Microbiol Spectr Observation Antimicrobial resistance continues to be a global issue. Pathogens, such as Burkholderia pseudomallei, have evolved mechanisms to efflux certain antibiotics and manipulate the host response. New treatment strategies are therefore required, such as a layered defense approach. Here, we demonstrate, using biosafety level 2 (BSL-2) and BSL-3 in vivo murine models, that combining the antibiotic doxycycline with an immunomodulatory drug that targets the CD200 axis is superior to antibiotic treatment in combination with an isotype control. CD200-Fc treatment alone significantly reduces bacterial burden in lung tissue in both the BSL-2 and BSL-3 models. When CD200-Fc treatment is combined with doxycycline to treat the acute BSL-3 model of melioidosis, there is a 50% increase in survival compared with relevant controls. This benefit is not due to increasing the area under the concentration-time curve (AUC) of the antibiotic, suggesting the immunomodulatory nature of CD200-Fc treatment is playing an important role by potentially controlling the overactive immune response seen with many lethal bacterial infections. IMPORTANCE Traditional treatments for infectious disease have focused on the use of antimicrobial compounds (e.g. antibiotics) that target the infecting organism. However, timely diagnosis and administration of antibiotics remain crucial to ensure efficacy of these treatments especially for the highly virulent biothreat organisms. The need for early antibiotic treatment, combined with the increasing emergence of antibiotic resistant bacteria, means that new therapeutic strategies are required for organisms that cause rapid, acute infections. Here, we show that a layered defense approach, where an immunomodulatory compound is combined with an antibiotic, is better than an antibiotic combined with a relevant isotype control following infection with the biothreat agent Burkholderia pseudomallei. This approach has the potential to be truly broad spectrum and since the strategy includes manipulation of the host response it's application could be used in the treatment of a wide range of diseases. American Society for Microbiology 2023-05-18 /pmc/articles/PMC10269878/ /pubmed/37199641 http://dx.doi.org/10.1128/spectrum.04016-22 Text en © Crown copyright 2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . To view this licence, visit http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk. |
spellingShingle | Observation Thom, R. E. Williamson, E. D. Casulli, J. Butcher, W. A. Burgess, G. Laws, T. R. Huxley, P. Ashfield, R. Travis, M. A. D’Elia, R. V. Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis |
title | Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis |
title_full | Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis |
title_fullStr | Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis |
title_full_unstemmed | Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis |
title_short | Assessment of CD200R Activation in Combination with Doxycycline in a Model of Melioidosis |
title_sort | assessment of cd200r activation in combination with doxycycline in a model of melioidosis |
topic | Observation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10269878/ https://www.ncbi.nlm.nih.gov/pubmed/37199641 http://dx.doi.org/10.1128/spectrum.04016-22 |
work_keys_str_mv | AT thomre assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT williamsoned assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT casullij assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT butcherwa assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT burgessg assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT lawstr assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT huxleyp assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT ashfieldr assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT travisma assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis AT deliarv assessmentofcd200ractivationincombinationwithdoxycyclineinamodelofmelioidosis |